Skip to content

How to Use Sermorelin: Administration, Reconstitution & Storage (2026)

From Peptidepedia, the trusted peptide wiki.

How to Use / Administration Methods

Sermorelin is administered via subcutaneous (SubQ) injection, typically into the abdominal fat pad, anterior thigh, or posterior upper arm.

Why bedtime dosing matters: The largest physiological GH pulse occurs during early slow-wave sleep, when hypothalamic somatostatin tone drops to its lowest point. Injecting sermorelin 15 to 30 minutes before bed synchronizes exogenous GHRH receptor stimulation with this natural secretory window, maximizing GH output. Administering sermorelin during the day, when somatostatin tone is high, substantially blunts the GH response.

Injection process:

  1. Reconstitute the lyophilized powder with bacteriostatic water (see Reconstitution section)
  2. Draw the prescribed dose into an insulin syringe (29 to 31 gauge, 0.5 or 1 mL)
  3. Clean the injection site with an alcohol swab
  4. Pinch a fold of skin and insert the needle at a 45 to 90 degree angle
  5. Inject slowly and steadily
  6. Withdraw the needle and apply gentle pressure with a clean swab if needed

Injection sites should be rotated to prevent lipodystrophy or local irritation. Administering on an empty stomach (at least 90 minutes after the last meal) is recommended, as elevated blood glucose and insulin can attenuate the GH response.

Reconstitution, Storage & Prep

Sermorelin is supplied as a lyophilized (freeze-dried) powder in sterile vials, typically in 2 mg, 3 mg, or 5 mg quantities. It requires reconstitution before use.

Reconstitution Process:

  1. Remove the sermorelin vial and bacteriostatic water from the refrigerator and allow both to reach room temperature (5 to 10 minutes)
  2. Wipe the rubber stopper of each vial with a sterile alcohol swab
  3. Using a sterile syringe, draw the appropriate volume of bacteriostatic water
  4. Insert the needle into the sermorelin vial and inject the water slowly against the glass wall, allowing it to run down gently. Never spray directly onto the powder
  5. Swirl the vial gently until the powder is fully dissolved. Never shake, as this can denature the peptide
  6. The solution should be clear and colorless; discard if cloudy or if particulate matter is visible

Common reconstitution ratio: 3 mg + 3 mL bacteriostatic water = 1 mg/mL (1,000 mcg/mL). For a 300 mcg dose at this concentration, draw 0.3 mL (30 units on a standard insulin syringe).

Storage Guidelines:

  • Unreconstituted powder: Stable at room temperature; refrigeration at 2 to 8°C (36 to 46°F) is recommended for long-term storage (12+ months)
  • Reconstituted solution: Must be refrigerated at 2 to 8°C (36 to 46°F); use within 4 to 6 weeks when reconstituted with bacteriostatic water
  • Never freeze reconstituted sermorelin. Ice crystal formation can permanently damage the peptide's tertiary structure
  • Temperature excursions: If left at room temperature for more than 72 hours after reconstitution, the vial should be discarded
  • Protect from light and heat at all times
  • Always use bacteriostatic water (containing 0.9% benzyl alcohol) rather than sterile water for multi-dose vials to prevent bacterial contamination

Frequently Asked Questions

Sermorelin was originally FDA-approved to diagnose and treat growth hormone deficiency in children. Today, it is prescribed off-label through compounding pharmacies for age-related growth hormone decline, body composition optimization, improved sleep quality, and general anti-aging support.

Both are GHRH analogs, but they differ significantly in half-life. Sermorelin has a half-life of about 11 to 12 minutes and requires daily injections. CJC-1295 with DAC has a half-life of 5 to 8 days, requiring only weekly dosing. CJC-1295 produces more sustained GH elevation, while sermorelin more closely mimics the body's natural pulsatile GH release pattern.

The most frequently reported side effects are mild injection site reactions (redness, swelling, itching), transient facial flushing lasting a few minutes, and headache, particularly during the first 1 to 2 weeks of therapy. Most side effects resolve as the body adjusts to treatment.

Improved sleep quality is often the first noticeable effect, typically within 1 to 2 weeks. Measurable changes in IGF-1 levels appear within 4 to 6 weeks. Body composition improvements, including fat loss and increased lean mass, generally require 3 to 6 months of consistent use.

Most anti-aging protocols use 200 to 300 mcg administered subcutaneously at bedtime, 5 nights per week. Dosing is individualized based on age, IGF-1 levels, and clinical response. A healthcare provider should determine the appropriate dose and monitor progress.

No. Sermorelin is a peptide that would be rapidly degraded by digestive enzymes if taken orally, rendering it inactive. It must be administered via subcutaneous injection to reach the bloodstream intact and exert its effects on the pituitary gland.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308.
  2. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157.
  3. Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96.
  4. Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37.
  5. Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 2020;9(Suppl 2):S149-S159.
  6. FDA. Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register. 2013;78(42):14219-14220.
  7. World Anti-Doping Agency. The 2025 Prohibited List International Standard.
  8. Sermorelin Acetate. RxList Drug Database.
  9. PubChem. Sermorelin (CID 16132413).
  10. Sermorelin. DrugBank (DB00010).

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”